Serum free prolactin concentrations in patients with systemic lupus erythematosus are associated with lupus activity

Rheumatology

Volumn 45, Issue 1, 2006, Pages 97-101

  Leaños Miranda, Alfredo ^a   Cardenas Mondragon G ^a  

^a Hospital Luis Castelazo Ayala   (Mexico)

Author keywords

Disease activity; Free prolactin; Isoforms of prolactin; Prolactin; Systemic lupus erythematosus

Indexed keywords

DOUBLE STRANDED DNA ANTIBODY; PROLACTIN;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DISEASE ACTIVITY; FEMALE; GEL FILTRATION CHROMATOGRAPHY; HEMATOLOGIC DISEASE; HUMAN; HYPERPROLACTINEMIA; HYPOCOMPLEMENTEMIA; IMMUNORADIOMETRIC ASSAY; INFLAMMATION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SCORING SYSTEM; SEROLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; CHROMATOGRAPHY, GEL; COMPLEMENT SYSTEM PROTEINS; CROSS-SECTIONAL STUDIES; DNA; FEMALE; HUMANS; HYPERPROLACTINEMIA; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PROLACTIN;

EID: 29844436772     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kei115     Document Type: Article

References (29)

1. Blanco-Favela F, Quintal-Alvarez G, Leaños-Miranda A. Association between prolactin and disease activity in systemic lupus erythematosus. Influence of statistical power. J Rheumatol 1999;26:55-9.
2. Jacobi AM, Rohde W, Ventz M, Riemekasten G, Burmester GR, Hiepe F. Enhanced serum prolactin (PRL) in patients with systemic lupus erythematosus: PRL levels are related to the disease activity. Lupus 2001;10:554-61.
3. Pacilio M, Migliaresi S, Meli R, Ambrosone L, Bigliardo B, Di Carlo R. Elevated bioactive prolactin levels in systemic lupus erythematosus - association with disease activity. J Rheumatol 2001; 28:2216-21.
4. Leaños-Miranda A, Pascoe D, Fraga A, Blanco-Favela F. Anti-prolactin autoantibodies in systemic lupus erythematosus patients with associated hyperprolactinemia. Lupus 1998;7:398-403.
5. McMurray R, Keisler D, Kanuekel K, Izui S, Walker SE. Prolactin influences autoimmune disease activity in the female B/W mouse. J Immunol 1991;147:3780-7.
6. McMurray R, Keisler D, Kondo K, Walker S. Hyperprolactinemia in male NZB/ NZW (B/W) F1 mice: Accelerated autoimmune disease with normal circulating testosterone. Clin Immunol Immunopathol 1994;71:338-43.
7. Peeva E, Grimaldi C, Spatz L, Diamond B. Bromocriptine restores tolerance in estrogen-treated mice. J Clin Invest 2000;106:1373-9.
8. Hattori N, Ikekubo K, Ishihara T, Moridera K, Hino M, Kurahachi H. Effects of anti-prolactin autoantibodies on serum prolactin measurements. Eur J Endocrinol 1994;130:434-7.
9. Leaños-Miranda A, Chávez Rueda KA, Blanco-Favela F. Biologic activity and plasma clearance of prolactin-IgG complex in patients with systemic lupus erythematosus. Arthritis Rheum 2001;44:866-75.
10. Garnier PE, Aubert ML, Kaplan SL, Grumbach MM. Heterogeneity of pituitary and plasma prolactin in man: Decreased affinity of 'big' prolactin in radioreceptor assay and evidence for its secretion. J Clin Endocrinol Metab 1978;47:1273-81.
11. Soong YK, Ferguson KM, McGarrick G, Jeffcoate SL. Size heterogeneity of immunoreactive prolactin in hyperprolactinemic serum. Clin Endocrinol (Oxf) 1982;16:259-65.
12. Tanaka T, Yano H, Umezawa S et al. Heterogeneity of big-big hPRL in hyperprolactinemia. Horm Metab Res 1989;21:84-8.
13. Jackson RD, Malarkey WB. Characterization of a large molecular weight prolactin in women with idiopathic hyperprolactinemia and normal menses. J Clin Endocrinol Metab 1985;61:258-64.
14. Leite V, Cosby H, Sobrinho LG, Fresnoza A, Santos MA, Friesen HG. Characterization of big big prolactin in patients with hyperprolactinemia. Clin Endocrinol 1992;37:365-72.
15. Whittaker PG, Wilcox T, Lind T. Maintained fertility in a patient with hyperprolactinemia due to big, big prolactin. J Clin Endocrinol Metab 1981;53:863-6.
16. Leaños-Miranda A, Pascoe-Lira D, Chávez Rueda KA, Blanco-Favela F. Persistence of macroprolactinemia due to anti-prolactin autoantibody, before, during, and after pregnancy in a woman with systemic lupus erythematosus. J Clin Endocrinol Metab 21;86:2619-24.
17. Cruz J, Aviña-Zuvieta A, Martínez de la Escalera G, Clapp C, Lavalle C. Molecular heterogeneity of prolactin in the plasma of patients with systemic lupus erythematosus. Arthritis Rheum 2001; 44:1331-5.
18. García M, Colombani-Vidal ME, Zylbersztein CC et al. Analyses of molecular heterogeneity of prolactin in human systemic erythematosus. Lupus 2004;13:575-83.
19. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
20. Bombardier C, Gladman D, Urowitz M, Caron D, Chang CH. The Committee on Prognosis Studies in SLE: Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992;35: 630-40.
21. Leaños-Miranda A, Pascoe-Lira D, Chávez- Rueda KA, Blanco-Favela F. Anti-prolactin autoantibodies in systemic lupus erythematosus: frequency and correlation with prolactinemia and disease activity. J Rheumatol 2001;28:1546-53.
22. Leaños-Miranda A, Pascoe-Lira D, Chávez-Rueda KA, Blanco-Favela F. Detection of macroprolactinemia with the polyethylene glycol precipitation test in systemic lupus erythematosus patients with hyperprolactinemia. Lupus 2001;10:340-5.
23. Leaños-Miranda A, Contreras-Hernández I. Antiprolactin autoantibodies are associated with hyperprolactinemia status in men infected with human immunodeficiency virus. Endocrine 2002;19: 139-46.
24. Fraser IS, Lun ZG. Polymers of prolactin and their clinical significance. Obstet Gynecol Surv 1990;45:515-20.
25. Sinha YN. Structural variants of prolactin: Occurrence and physiological significance. Endocr Rev 1995;16:354-69.
26. Pascoe-Lira D, Duran-Reyes G, Contreras-Hernández I, Manuel-Apolinar L, Blanco-Favela F, Leaños-Miranda A. Frequency of macroprolactinemia due to autoantibodies against prolactin in pregnant women. J Clin Endocrinol Metab 2001;86:924-9.
27. McMurray R, Weidensaul D, Allen S, Walker S. Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus. J Rheumatol 1995;22:2084-91.
28. Alvarez-Nemegyei J, Covarrubias-Cobos A, Escalante-Triay F, Soza-Munoz J, Miranda JM, Jara LJ. Bromocriptine in systemic lupus erythematosus: A double-blind, randomized, placebo-controlled study. Lupus 1998;7:414-9.
29. Peeva E, Michael D, James C, Rice J, Chen X, Diamond B. Prolactin modulates the naïve B cell repertoire. J Clin Invest 2003;111:275-83.